October 21, 2024 – Talk Bio

Vertex’s Non-Opioid Pain Drug Suzetrigine Nears FDA Approval: A Breakthrough in Acute Pain Management

6 months ago talkbio0Tagged acute pain management, addiction, Approved, Feeling relief, non-opioid pain drug, Opioid Epidemic, Pain, Risk, signal inhibitor, Suzetrigine, United States Food and Drug Administration

Suzetrigine, Non-opioid pain drug, Acute pain management, FDA approval, Vertex Pharmaceuticals, NaV1.8 pain signal inhibitor, Opioid epidemic, Pain relief without addiction risk

Noom and Waltz Health Collaborate on Affordable GLP-1 Weight Loss Program

6 months ago talkbio0Tagged Glucagon-Like Peptide 1, Health, Medication Management, Noom, Obesity

Noom, Waltz Health, GLP-1, weight loss, affordable, medication management, obesity treatment

Vertex’s Non-Opioid Pain Drug, Suzetrigine (VX-548), Shows Promising Results in Phase III Trials, Aiming for FDA Approval

6 months ago talkbio0Tagged Acute onset pain, Approved, non-opioid pain drug, Opioids, Phase 3 Clinical Trials, Suzetrigine, United States Food and Drug Administration, VX-548

Non-opioid pain drug, Suzetrigine (VX-548), Vertex Pharmaceuticals, Phase III trials, acute pain, FDA approval, opioid alternative

Seaport Therapeutics Secures $225 Million in Oversubscribed Series B Funding

6 months ago talkbio0Tagged Glyph technology platform, Investments, neuropsychiatric medicines, Seaport, Series B

Seaport Therapeutics, Series B funding, neuropsychiatric medicines, Glyph technology platform, biotech investment

Novo Nordisk’s Alhemo Nears EU Approval: A Breakthrough in Haemophilia Treatment

6 months ago talkbio0Tagged Alhemo, CHMP, concizumab, European Medicines Agency, Haemophilia A and B, inhibitors, Nordisk, Subcutaneous prophylactic treatment

Novo Nordisk, Alhemo, Haemophilia A and B, Inhibitors, European Medicines Agency (EMA), CHMP positive opinion, Subcutaneous prophylactic treatment, Concizumab